Ascendis Pharma vs Exelixis

Ascendis Pharma (ASND), health care, and Exelixis (EXEL), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Ascendis Pharma is worth $17.8B on the stock market and Exelixis $16.7B: Ascendis Pharma is valued at 6% more. Ascendis Pharma trades at 17.8 times earnings and Exelixis at 20.5; operating margins in their latest fiscal years were -18.9% and 37.6%. Over the past year Ascendis Pharma's share price has moved +25.1% and Exelixis's +57.3%.

Key facts

Ascendis Pharma market value
$17.8B
Exelixis market value
$16.7B
Ascendis Pharma P/E
17.8
Exelixis P/E
20.5
Ascendis Pharma revenue
$799MFY to 2025-12-31
Exelixis revenue
$2.3BFY to 2026-01-02
Superinvestors holding both
0

Market values as of .

Ascendis Pharma vs Exelixis: every measure side by side
Measure Ascendis Pharma Exelixis
SectorHealth CareHealth Care
Country Denmark United States
Fiscal year ends2025-12-312026-01-02
Size
Market cap$17.8Bhigher$16.7Blower
Revenue$799Mlower$2.3Bhigher
Earnings-$253Mlower$782.6Mhigher
Employees1,189higher1,077lower
Total assets$1.4Blower$2.8Bhigher
Valuation
P/E17.8lower20.5higher
P/S22.3higher7.2lower
P/B—9.1
Dividend yield—0.00%
Profitability
Operating margin-18.9%lower37.6%higher
Balance sheet
Net assets-$180.7Mlower$2.2Bhigher
Total liabilities$1.6Bhigher$683.1Mlower
Total debt$799.1M—
Cash on hand$683.5Mhigher$482.5Mlower
Price change
Today-0.20%lower+2.09%higher
1 year+25.1%lower+57.3%higher

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (0)

None of the tracked investors.

Ascendis Pharma only (2)

Percentages are each holding's share of that investor's reported portfolio. Who owns ASND · Who owns EXEL

Further comparisons

Learn

Questions and answers

Which is bigger, Ascendis Pharma or Exelixis?

By market value, Ascendis Pharma is the larger: $17.8B against $16.7B for Exelixis. By revenue in its latest fiscal year, Exelixis is the larger: $2.3B against $799M for Ascendis Pharma.

Which has the higher P/E ratio?

Exelixis: 20.5, against 17.8 for Ascendis Pharma. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

Which has the higher operating margin?

Exelixis: 37.6%, against -18.9% for Ascendis Pharma. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which superinvestors own both Ascendis Pharma and Exelixis?

None of the tracked superinvestors holds both in their latest 13F filing. 2 hold Ascendis Pharma and 5 hold Exelixis.

Cite this page

Funkfolio, “Ascendis Pharma vs Exelixis”, data as of 18 November 2026. https://funkfolio.com/compare/asnd-vs-exel

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.